Innate Pharma (IPHA) Shares Outstanding (Diluted Average) (2018 - 2025)
Innate Pharma (IPHA) reported Shares Outstanding (Diluted Average) of $282.99 for Q2 2025, down 15.23% on a YoY basis from $333.84 in Q2 2024, and down 15.23% quarter-over-quarter from $333.84 in Q2 2024.
Innate Pharma (IPHA) Shares Outstanding (Diluted Average) (2018 - 2025) Analysis & Trends
Innate Pharma has reported Shares Outstanding (Diluted Average) for 8 years, with the latest figure at $282.99 in Q2 2025.
- For the quarter ending Q2 2025, Shares Outstanding (Diluted Average) fell 15.23% year-over-year to $282.99; the trailing twelve-month figure through Jun 2025 stood at $282.99 (down 15.23% YoY), and the FY2018 full-year result was $650.6, changed N/A from the prior year.
- Shares Outstanding (Diluted Average) for Q2 2025 stood at $282.99, down from $333.84 in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $95.1 million in Q2 2021, with the low at $21.78 in Q2 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $19.0 million across 5 years, with a median of $282.99 in 2025.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Diluted Average) jumped 66439666.22% — and 2022, when it sank 100.0%.
- Innate Pharma's Shares Outstanding (Diluted Average) stood at $95.1 million in 2021, then slumped by 100.0% to $85.36 in 2022, then slumped by 74.49% to $21.78 in 2023, then soared by 1432.87% to $333.84 in 2024, then declined by 15.23% to $282.99 in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $282.99 (Q2 2025), $333.84 (Q2 2024), and $21.78 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 92.44 Mn |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 282.99 |
| Jun 30, 2024 | 333.84 |
| Jun 30, 2023 | 21.78 |
| Jun 30, 2022 | 85.36 |
| Jun 30, 2021 | 95.13 Mn |
| Jun 30, 2020 | 143.19 |
| Jun 30, 2019 | 22,472.78 |
| Dec 31, 2018 | 650.60 |